Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia

Adult patients with relapsed/refractory (R/R) B‐precursor acute lymphoblastic leukemia (ALL) have a poor prognosis. Blinatumomab is a bispecific T‐cell engager (BiTE) immuno‐oncology therapy with dual specificity for CD19 and CD3 that redirects patients’ CD3‐positive cytotoxic T cells to lyse malign...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiyoi, Hitoshi, Morris, Joan D., Oh, Iekuni, Maeda, Yoshinobu, Minami, Hironobu, Miyamoto, Toshihiro, Sakura, Toru, Iida, Hiroatsu, Tuglus, Catherine A., Chen, Yuqi, Dos Santos, Cedric, Kalabus, James, Anderson, Abraham, Hata, Tomoko, Nakashima, Yasuhiro, Kobayashi, Yukio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156857/
https://www.ncbi.nlm.nih.gov/pubmed/31971321
http://dx.doi.org/10.1111/cas.14322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156857/
https://www.ncbi.nlm.nih.gov/pubmed/31971321
http://dx.doi.org/10.1111/cas.14322

Ejemplares similares